Pharmacogenetic testing in schizophrenia and posttraumatic stress disorder.
Genotyping patients prior to beginning psychiatric pharmacological therapy can serve to inform practitioners as to each patient's likelihood of therapeutic response and their relative risk of experiencing toxicity and other adverse side effects from certain drugs. Such information could arm physicians with the knowledge they need to make appropriate drug and dosing decisions and avoid the lengthy trial-and-error process with which they are faced today. This article describes the current state of pharmacogenetic testing in schizophrenia and posttraumatic stress disorder.
Ramey-Hartung
Bronwyn
B
PGXL Laboratories, Louisville, KY 40202, USA. bronwyn.ramey@pgxlab.com
El-Mallakh
Rifaat S
RS
Reynolds
Kristen K
KK
D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D003863:Depression / Q000188:drug therapy / Q000235:genetics; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D011110:Polymorphism, Genetic; D011570:Psychiatry / Q000379:methods / Q000639:trends; D044263:Receptors, Serotonin, 5-HT1 / Q000235:genetics; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome
D044263:Receptors, Serotonin, 5-HT1; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D003577:Cytochrome P-450 Enzyme System